Skip to main content

WEB ACCESSIBLE MR DECISION SUPPORT SYSTEM FOR BRAIN TUMOUR DIAGNOSIS AND PROGNOSIS, INCORPORATING IN VIVO AND EX VIVO GENOMIC AND METABOLIMIC DATA

Objective

Diagnosis and treatment of brain tumours is based on clinical symptoms, radiological appearance, and often a histopathological diagnosis of a biopsy. However, treatment response of histological or radiologically similar tumours can vary widely, particularly for childhood tumours. New technologies are available that may improve tumour classification in terms of diagnosis and prognosis, and may allow individually optimised treatments.

Magnetic Resonance Spectroscopy (MRS) is a non-invasive technique for determining tissue biochemicals (the metabolomic profile). MRS can be performed along with clinical MR Imaging but widespread use is hampered by specialised analysis requirements and poor dissemination of the skills needed to interpret the data. The genomic profile of tumours can be determined with DNA microarrays. Early studies have demonstrated differences in gene expression between tumour grades and between tumour types not easily distinguished by morphologic appearance.

We will bring together the expertise required to study the genomic and metabolomic characteristics of brain tumours, with a multi-centre collaboration to acquire statistically significant data, particularly for rare tumour types. Clinical MRS, high-resolution 1H MRS and gene array analysis of biopsies, will be used to investigate how metabolomic and genomic profiles relate to clinically relevant factors such as survival time and treatment response. As well as providing new scientific data on tumour biology, we will develop the technology for this information to be readily and easily used to help radiologists and neurosurgeons in the management and treatment of brain tumour patients. We will build upon expertise obtained with INTERPRET EU project IST-1999-10310, which created a MRS decision support tool (DSS) for tumour diagnosis. A new web-accessible DSS will be developed, incorporating genomic and metabolomic data, and its diagnostic performance validated.

Call for proposal

FP6-2002-LIFESCIHEALTH
See other projects for this call

Funding Scheme

IP - Integrated Project

Coordinator

UNIVERSITAT DE VALENCIA - ESTUDI GENERAL
Address
Avda. Blasco Ibañez, 13
Valencia
Spain

Participants (18)

BRUKER BIOSPIN SA.
France
Address
34 Rue De L'industrie
Wissembourg Cedex
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Germany
Address
Im Neuenheimer Feld 280
Heidelberg
FUNDACIÓN PARA LA LUCHA CONTRA ENFERMEDADES NEUROLÓGICAS DE LA INFANCIA
Argentina
Address
Montañeses 2325
Ciudad Autonoma De Buenos Aires
HOSPITAL SANT JOAN DE DÉU
Spain
Address
Passeig Sant Joan De Déu, 2
Esplugues De Llobregat (Barcelona)
HYPERPHAR GROUP SPA
Italy
Address
Via Pascoli 60
Milan
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
France
Address
Rue De Tolbiac 101
Paris
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
Oude Markt 13
Leuven
MEDICAL UNIVERSITY LODZ
Poland
Address
Kosciuszki, 4
Lodz
MICROART, S.L.
Spain
Address
Viladomat, 291
Barcelona
PHARMA QUALITY EUROPE, S.R.L.
Italy
Address
Via Dei Poggi, 1
Catelfranco Di Sopra (Arezzo)
SCITO S.A.
France
Address
5 Place Robert Schuman
Grenoble
SIEMENS AG, MEDICAL SOLUTIONS
Germany
Address
Henkestrasse 127
Erlangen
ST GEORGE'S HOSPITAL MEDICAL SCHOOL'
United Kingdom
Address
Cranmer Terrace
London
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
Address
Geert Grooteplein 10
Nijmegen
THE UNIVERSITY OF NOTTINGHAM
United Kingdom
Address
University Park
Nottingham
UNIVERSIDAD POLITÉCNICA DE VALENCIA
Spain
Address
Camino De Vera S/n
Valencia
UNIVERSITAT AUTÒNOMA DE BARCELONA
Spain
Address
Campus Universitat Autònoma De Barcelona
Bellaterra (Cerdanyola Des Vallès)
UNIVERSITY OF BIRMINGHAM
United Kingdom
Address
Edgbaston
Birmingham